Article Type : Research Article
Authors : Zervos M, Lepetsos P and Zafeiris C
Keywords : Osteoblasts; Bone metastatic Disease
The main function of osteoblasts is new
bone production during the process of skeletal growth and bone remodelling.
During bone remodelling, osteoblasts interact directly with other osteoblasts
and other bone cells, such as osteoclasts, osteocytes, and mesenchymal stem
cells, through complex cellular mechanisms. With the contribution of these
mechanisms, osteoblasts and osteoclasts are responsible for the preservation of
a balance between bone production and bone resorption. Bone metastatic disease
is a frequent and unpleasant event in advanced stages of malign tumors. When
the tumor cells spread to the bone microenvironment, they use the specific
cellular mechanisms, disrupting the homeostasis of the bones. The cross-talk
among cancer cells and bone tissue cells is crucial in the maintenance of the
metastatic process, including the initial survival and seeding of disseminated
tumor cells, activation of inactive micro metastatic lesions, and outspread of
osteoblastic or osteolytic metastases. The aim of this review is to describe
the role of osteoblasts in bone metastatic disease.
During embryonic
skeletogenesis and bone remodelling, osteoblasts are the bone cells that
produce bone tissue. In order to regulate bone formation, osteoblasts produce
ECM type I collagen. In addition, they also produce non-collagen proteins such
as osteonectin and osteocalcin. For bone ossification, osteoblasts produce
growth factors, enzymes and hormones including ALP, MMPs, TGF-?, and IGFs [1].
The combined action of the transcription factors Runx2 and Osx is demanded for
the MSCs differentiation to osteoblasts (1). MSCs have the potential to
differentiate into cells of mesodermal origin such as chondrocytes, osteoblasts
and adipocytes. The connection of osteoprogenitor cells and mesenchymal cells
triggers the differentiation of osteoblasts. Gradually, they differentiate into
mature functional osteoblasts that express osteoblast genes and finally they
are converted to osteocells, embedded into the bone ECM within the bone marrow.
The regulation of osteoblastic differentiation is performed through osteogenetic
signalling pathways [2]. Runx2 is a transcription factor, vital for bone
formation. Its expression is necessary for the differentiation of MSCs into
cells of the osteoblastic series. Runx2 binds to the promoter region (OSE-2) of
osteoblast genes. Runx2 is expressed very early in skeletal development, in
assemblages of MSCs in areas destined for bone tissue. It is also expressed
during the postmenopausal period during bone production. Inactivation of the
Runx2 gene in Runx2-/- mice results in complete absence of mature osteoblasts,
suppressing intramembranous and endochondral ossification. MSCs in these
animals may further differentiate into chondrocytes and adipocytes [2]. Osx,
?-catenin, ATF4, and DLX5 are additional transcription factors that control osteoblast
genesis. They work primarily with Runx2 and guide osteoprogenitor cells in
their differentiation to the osteoblastic lineage. Activation of the Wnt /
?-catenin signalling pathway stimulates bone production by osteoblasts,
inducing the gathering of ?-catenin and its transportation to the nucleus,
where it connects to LEF / TCF transcription factors by activating genes
including Runx2 [3]. Suppression of ?-catenin reduces MSCs differentiation to
osteoblasts, indicating that ?-catenin is a key molecule in osteoblastic
differentiation. NF-?B is transported to the nucleus of osteoblasts, activating
specific osteoblastic genes. NF-?B acts via the RANK-RANKL pathway and mainly
controls osteoblast differentiation [4]. Three families of growth factors affect
osteoblastic activity: TGF-?, IGFs and BMPs. They act mainly through their own
interactions, through interactions with hormones or through specialized
intracellular mediators that ultimately act on transcription factors. FGFs
control specific elements of endochondral bone formation in the early stages of
skeletogenesis. They stimulate osteoblast replication, but tend to reduce new
bone formation by reducing collagen synthesis. Ihh protein controls the
expression, function and phosphorylation of Runx2 and therefore the
transcription of osteoblastic genes. BMPs stimulate bone formation in vivo by
enhancing the expression of Runx2 in MSCs and prosteoblasts, and Osx in
osteoblasts. TGF-? has a significant role in osteoblastic differentiation by
promoting bone formation via Runx2 and at the same time by reducing the levels
of those transcription factors that promote lipogenesis [5,6]. Once the bone
production process is complete, the osteoblasts either turn into osteocytes,
remain dormant, trapped inside bone ECM, or undergo cellular apoptosis [7,8].
Osteocytes communicate with other osteocytes as well as with osteoblasts,
through extensive cytoplasmic extensions which form tiny channels (canaliculi)
within bone ECM. All of the aforementioned cells produce RANKL [9]. Therefore,
the interactions between RANKL, osteoclasts, osteoblasts and osteocytes
directly influence differentiation of osteoclasts, maintaining osteoclastic
bone resorption, and the production of growth factors from bone ECM.?
Colonization
and growth of metastatic cancer cells: Role of the bone microenvironment
Bones are a common area
of malign tumor metastases, affecting more than 300,000 patients annually in
the United States. Prostate and breast cancer are responsible for the 65-80% of
bone metastases [10]. When cancer cells escape from the primary cancer sites
and spread to distant areas, only a very small percentage survive in the
circulation and end up in the secondary organ-targets. The locations of the
metastases are not random. In order to grow, cancer cells must reach an
environment that is acceptable for colonization and subsequent growth. To do
that, cancer cells hijiack normal host functions, express ECM molecules and
mobilize bone marrow MSCs, thus creating the so-called “pre-metastatic niche”
[11]. Metastatic time of dormancy is a stage of cancer evolution where cancer
cells that have disseminated from a primary cancer site to peripheral areas may
remain in a state of inactivation for years [12]. In the case of bone
metastases, the cancer cells are thought to nest in specific niches, which
determine their fate [13,14]. Experimental data show that all of the following
niches have an important role in bone metastases and that the cross-talk among
these sites determines the activation or inactivation of cancer cells.
•
The
endosteal niche, consisting mainly of osteoblasts
•
The
hematopoietic stem cells (HSC) niche
•
The
perivascular niche and
•
The
bone marrow adipocyte niche
Endosteal Niche
In experimental studies,
prostate and breast cancer cells have been located in bone areas with abundance
in osteoblasts. In experimental models of breast cancer, administration of
zoledronic acid modifies the endosteal niche resulting in repositioning of
cancer cells in new bone sites rich in osteoblasts [15,16]. Osteoblasts release
the protein CXCL12, also known as SDF-1. On the other hand, the CXCL12
receptor, which is called fusin or CXCR4, is expressed by the majority of
metastatic breast and prostate cancer cells. The interaction between CXCL12 and
its receptor is vital for the binding of cancer cells to the endosteal
metastatic niche. Once cancer cells install the endosteal niche, osteoblasts
keep these cancer cells inactive through CXCR4 / CXCL12 cross-talk, with the
same mechanisms used for HSCs inactivation [17]. These osteoblasts are
spindle-shaped, positive for N-cadherin. Their binding to cancer cells and the
secretion of inhibitory proteins from stromal cells, such as fibronectin, also
maintains the state of dormancy of cancer cells. The action of CXCL12 is
regulated by NF-?B and the different response of cancer lines to CXCL12 is
probably the result of different degrees of NF-?B activation, which with in
turn is affected by the expression of androgen receptors in the cell [18].
Hematopoietic
stem cell (HSC) niche
Scattered cancer cells
tend to migrate into the endosteal bone surface, a niche where
non-proliferating HSCs are located. The HSC niche is also abundant in CXCL12,
therefore binding to CXCR4 (+) cancer cells in the same manner as the endosteal
metastatic niche. When cancer cells colonize the HSC niche, they compete with
HSCs for installation in the surface. The following outspread of cancer cells
outside the niche, allowing the onset of active metastases, is attained by the
mobilization and multiplication of HSCs, a process supported by the
perivascular niche [17,19].
Perivascular
niche
The perivascular niche
has been another site for colonization and accommodation of dormant cancer
cells. Within the perivascular niche, cancer cells are located at central
points within the bone marrow. Isolated evaluation of the perivascular niche is
difficult because of its proximity to the endosteal niche and the HSC niche. In
brain metastases deriving from breast and lung cancer, the cancer cells, after
extravasation, remain close to the capillary vessels [20,21]. These metastatic
cancer cells spread along the basement membrane around the capillaries and
multiply, encapsulating and reshaping the capillary vascular network [21].
Taking all these into account, it turns out that the endosteal niche is
important for maintaining the inactivity of the cancer cells, while the HSC
niche and the perivascular niche activate the proliferation of cancer cells in
active metastases. Thus, it is possible that bone metabolism and activity of
osteoblasts regulate the activation of bone metastases from cancer cells that
have spread to the bone microenvironment, an observation that has long been
made in animal studies [22,23].
Bone
Marrow Adipocyte niche
Adipocytes within the
bone marrow play a crucial role in the metastatic niche. Their number increases
during aging, making the adipocyte niche crucial in the elderly patients who
suffer from breast cancer. In an experimental study, breast cancer cells were
found to interact directly with bone marrow adipocytes, after their migration
into the bone marrow adipose tissue. This interaction was mediated by adipose
tissue-derived leptin and IL-1? [24].
Activation
of metastatic cells
When cancer cells
ultimately depart from the primary tumors and scatter into distant areas, only
few of them (below 0.1%) survive during circulation, escape immune
surveillance, and end up in the secondary targets [25]. Once installed in the
bones, the cancer cells affect the bone cells in two main ways. Usually, cancer
cells stimulate osteoclast genesis, increasing the differentiation and activity
of osteoclasts, while at the same time inhibiting osteoblasts [8]. When this
occurs, osteoclastic bone resorption overdraws osteoblastic bone formation,
leading in bone destruction and the creation of osteolytic lesions. Activated
osteoclasts trigger the increased proteolytic activity of MMP-9 and cathepsin
K, which inactivate the SDF-1 receptor and osteopontin, facilitating the
detachment of metastatic cancer cells from the endosteal niche [26,27].
Occasionally, instead of suppressing osteoblastic activity, cancer cells
secrete molecules that activate the osteoblast cell line, increasing osteoblast
differentiation and bone production. IL-6, PTHrP, EGF, TGF? and CSF are soluble
molecules that favour osteolysis. On the other hand, ET-1, BMPs, IGF?, BDGF
favour bone formation. Prostaglandins, TNF?, TGF?, IL-1 and PDGF may enhance
either bone production or bone resorption [28]. When bone production by
osteoblasts exceeds bone resorption by osteoclasts, increased bone formation
leads to "bulges" of the mineralized bone, where the cancer cells
multiply causing osteoblastic metastases. As osteoblastic bone lesions are
characterized by increased bone resorption and formation of weakened bone with
disrupted architecture, osteoblastic metastases are associated with increased
fracture risk [29]. Although osteolytic metastases are more common, the
distinction between osteolytic and osteoblastic metastases is incomplete and in
many cases, bone metastases have both osteoblastic and osteolytic lesions [30].
Osteoblasts may have a direct role on growth of bone metastases. In
experimental models of breast cancer bone metastasis, PTH administration
resulted in an increase in numbers of actively proliferating bone metastases
without modifying the dissemination of cancer cells in bone [31]. On the
contrast, daily administration of PTH inhibited cancer progression whilst
increasing bone production, in animal models of multiple myeloma [32].
Role
of osteoblasts in osteolytic metastases
Osteolytic metastases are
the most common type of bone metastases. They occur in solid cancers (lung,
prostate, breast, thyroid, kidney) and in haematological malignancies. The
osteolytic element is predominant but foci of osteoblastic activity coexist as
evidenced by elevated serum ALP levels. Metastatic cells within the bone marrow
do not act directly on the bone but they may modify osteoclastic and
osteoblastic function. In comparison with osteoclasts, the role of osteoblasts
in osteolytic metastases is rather limited. Upon the influence of breast cancer
cells, osteoblasts secrete chemokines and growth factors acting on both breast
cancer cells and osteoclasts, stimulating the vicious circle of bone metastatic
disease and osteolytic lesions [33]. In osteolytic bone metastases, cancer
cells release molecules that enhance osteoclastic activity by activating the
RANKL / RANK pathway. In addition, cancer cells produce activin A, DKK-1 and sclerostin
that suppress osteoblastic activity and differentiation [30]. DKK-1 produced by
myeloma cells has been found to inhibit the differentiation of osteoblasts,
induces the early differentiation of MSCs and therefore reduces their
viability. As the disease progresses, these events upset the balance between
osteoblasts and osteoclasts, reducing bone formation and enhancing bone
resorption [34]. Moreover, tumor cells induce osteoblasts apoptosis. This
causes disequilibrium between bone destruction and bone production in favour of
increased bone degradation. Increased bone destruction triggers a vicious
circle among cancer cells and osteoblasts, where growth factors (TGF-?, IGF),
that had been deposited in the bones by osteoblasts, are secreted from resorption
cavities, triggering cancer cell multiplication. Accordingly, tumor cells,
further secrete growth factors promoting bone metabolism. Through the dense,
interconnected vascular system, bone metaphysis provides plentiful growth
factors, such as TGF-?, whose production from bone directly induces the release
of PTHrP by cancer cells, stimulating RANKL production [35-37]. Osteoblasts
express CXCL12 and RANKL that promote dissemination of breast cancer cells and
evolution of bone metastases [38]. Initiation of bone resorption is mediated by
pre-osteoblasts producing RANKL, which enhances osteoclast genesis [39]. In
vitro experiments have shown that human breast cancer cells induce the
activation of the COX-2/PGE2 system and stimulate the increase of RANKL in
osteoblasts ultimately leading to osteolysis. Osteoblasts are stimulated by
both soluble agents and intercellular interactions. Removal of stimulation
using antibodies to ?1 integrin’s suggests their possible involvement in this
process [40]. At the initial stages, when the size of tumors is small, an
increase in osteoclastic activity and elimination of osteoblasts at the tumor /
bone interface, are observed. The compensation for this local increase in bone
resorption growth factors by absorbed bone triggers osteoblast genesis on the
adjacent bone surface, causing a local increase in RANKL production that
stimulates osteoclasts [41]. The simultaneous culture of osteoblasts and
osteoclasts enhances the stimulatory effect of PGE2 due to increased RANKL and decreased
OPG in osteoblasts. Additionally, osteoclast genesis is stimulated by the COX-2
/ PGE2 system through the increase of IL-6 secreted by osteoclasts and
osteoblasts [42]. This is the point when bone metastases develop while at the
advanced stages of metastatic disease, the role of osteoclasts dominates. After
the establishment of osteolytic metastases in bone, the release of TGF-? from
resorption cavities attenuates osteoblast genesis, thereby suppressing bone
formation, and further contributing to metastatic bone disease [43].
Quantitative
histomorphometric analysis of bone biopsies showed that in addition to a
decrease in number of osteoclasts, there was a decrease in the number of
osteoblasts, the surface and the absolute volume of the osteoid, and an
increase in bone cavities lacking osteocytes in the area around the metastatic
lesion [44]. In addition, another study indicated that elimination or
disruption of osteoblastic activity is observed near the metastatic site [45].
Osteoblasts have been found to surround breast cancer micro metastases. The
cross-talk between breast cancer cells and osteoblasts is affected by junctions
by N-cadherins and E-cadherins leading to increased mTOR activity in tumour
cells and ultimately to the awakening of inactive cancer cells and transition
into active metastases [38]. As previously mentioned, Runx2 is an important
factor for the differentiation and function of osteoblasts during skeletal
formation. Evidence for the role of Runx2 in osteotropy was obtained indirectly
when the expression of target genes (MMP-3, bone sialoprotein) was detected in
bone metastases [46,47]. According to these studies, Runx2 is indeed involved
in the expression of these genes, giving cancer cells osteomimetic
characteristics. The resulting osteolytic metastases were characterized by
inhibition of osteoblast differentiation and enhanced osteoclastogenesis. These
effects were eliminated when corresponding cancer cell lines expressing a
shorter, non-functional Runx2 were used.
Role
of osteoblasts in osteoblastic metastases
They are the most
frequent type of bone metastasis in prostate cancer and are less common in
breast cancer (15-20%), colon, pancreas and cervix. They are characterized by a
disturbance of the normal balance of bone tissue, with a predominance of the
osteoblastic bone formation. However, the produced bone does not have a normal
architecture resulting in an increased rate of fractures combined with severe
pain. In osteoblastic bone metastases, there is also a vicious circle among
cancer cells and bone cells, as happens in osteolytic disease. However, in
addition, cancer cells in the bones produce osteoblast stimulants such as BMPs,
EGFs and PDGFs. Prostate cancer cells produce various growth factors (TGF-?,
FGF-9, BMP-4, PDGF, VEGF, FGF), which promote the multiplication and
differentiation of osteoblasts, inducing the growth of prostate cancer cells
[26,27]. Runx2 has been found to be expressed in prostate cancer cells from
bone metastases [48]. Prostate cancer cells also produce FGF inducing
osteoblast apoptosis [49]. These activated osteoblasts release signalling
molecules such as MCP-1, IL-6, and MIP-2, which further enhance the
colonization and proliferation of tumor cells within the bone microenvironment.
Prostatic osteoblastic metastases are caused by the strong interaction among
prostate cancer cells and osteoblasts. Natural contact of osteoblasts with
cancer cells promotes the proliferation of prostate cancer cells in vitro [50].
In another study, the co-culture of osteoblasts and prostate cancer cells
caused a decrease in prostate cancer cell growth [51]. Another study showed
that molecules secreted by osteoblasts inactivated prostate cancer cells in
vitro and in vivo [52]. Experimental data have underlined that osteoblasts have
growth inhibitory properties, a feature that can be used both to promote the
delay of bone metastases and to prevent the progression of bone metastases
[53]. Circulating met prostate cells are associated with the endosteal bone
surface where they connect with osteoblasts via bonding with the annexin-2
receptor [54]. These micro-metastasic lesions form in areas of new bone tissue
production, where differentiated and active osteoblasts are sited. Moreover,
the interaction among osteoblasts and breast cancer cells has been shown that
molecules secreted during osteoblasts differentiation process enhance cancer
cell growth. VEGF is involved in osteoblastic metastases. Based on findings
that VEGF stimulates osteoblastic activity and induces bone remodeling,
Kitakawa et al suggested that prostate cells initially support the
proliferation of cancer cells in the bone through VEGF secretion [55]. In a
second stage, continued VEGF secretion triggers the activation of
pro-osteoblasts to mature, active osteoblasts through its binding to
neuropilin-1 [56]. However, it has not been shown that VEGF alone can induce
the formation of osteoblastic metastasis, but apparently cooperates with other
factors such as BMP, Wnt and ET-1.
In 1995, Nelson et al correlated ET-1 with
osteoblastic metastases of prostate cancer by finding elevated serum levels in
patients [57]. It is hypothesized that cancer cells of bone metastasis secrete
ET-1, which stimulates the proliferation of osteoblasts and consequently new
bone formation. In turn, stimulated osteoblasts in turn enrich the bone
microenvironment with growth factors (IL-1?, IL-1?, EGF, TNF?, TGF-?), which
further enhance the production of ET-1 by tumor cells, thus closing a vicious
circle, resulting in the formation of osteoblastic metastasis [58]. Moreover,
tumor cells produce ET-1, downregulating DKK-1 factor biosynthesis and
stimulating osteoblastogenesis [43]. Prostate cancer cell function is affected
by factors secreted by osteoblasts, such as osteopontin, osteonectin, osteocalcin,
and bone sialoprotein [26,27]. Osteonectin has a chemotactic effect on various
types of cancer. In a study with tissue extracts, it was concluded that bone
enhances movement of prostate cancer cells [59]. Similar findings exist for the
directed migration of breast cancer cells. Osteopontin is another protein that
is overexpressed in bone ECM and plays a role in the chemotaxis of cancer
cells. Its role in the directed migration of cancer cells is mainly regulated
by integrin ?v?3 and includes cancers such as melanoma and breast cancer, while
there is a possible role of the integrin ?1 chain in combination with ? chains
[60]. This migration depends on at least two growth factors and their receptors
(HGF / c-met axis, EGF and their ligands) as well as multiple signaling
pathways [61]. In bone metastatic lesions, osteopontin mRNA has been detected
in cancer cells which are in contact with the bone, possibly mediating
interactions at tumor-host interface. Berger et al. using antisense
oligonucleotides, reduced the expression of both osteopontin and bone
sialoprotein in human breast cancer cells, thereby inhibiting the formation of
osteolytic metastases [62]. Studies in the same cellular type have shown a
great increase in metastatic capacity in the presence of high osteopontin
levels [63]. Also, intravenous infusion of B16 melanoma cells in osteopontin
deficient mice led to reduced bone metastatic lesions compared to normal mice
[64]. In addition, binding of osteopontin to ?v?3 integrin induces osteoblast activation
in osteolytic metastases [65]. There have been reports of a possible role for
osteopontin as a factor in inducing osteoblast apoptosis [66]. The central role
of osteopontin in the metastatic process has led to the search for possible
therapeutic applications targeting either osteopontin itself or its receptors
(CD44 and integrins). The fact that osteopontin produced by cancer cells
differs from endogenous osteopontin makes this molecule attractive as a
therapeutic target. Bone sialoprotein is another of the non-collagenous
proteins of bone marrow that plays a significant role in the chemotaxis of
cancer cells to bone tissue. Over time, both host as well as cancer
cell-derived bone sialoprotein have been involved in the metastatic process.
Tumor cells probably attach to the bone ECM by a mechanism similar to that of
osteoclasts through integrins interaction [67]. A study in breast cancer cells
has shown that this is achieved by binding to integrin ?v?3 and depends on an
arginine-glycine-asparagine tripeptide (RGD). However, the involvement of
regions independent of the RGD tripeptide is also possible [68,69]. Similar
data exist for melanoma cells [70]. Ectopic expression of bone sialoprotein is
probably due to the activation of intracellular pathways and the action of the
transcription factors Runx2 and MSX2. There is evidence that bone sialoprotein
may be involved in the angiogenetic process of the metastatic lesions [71]. The
aforementioned increased osteoblastic activity leads to an increase in calcium
and phosphorus deposition, causing hypocalcaemia, resulting in increased PTH
secretion (secondary hyperparathyroidism), which activates the production of
RANKL in MSCs and osteoblasts, enhancing osteoclastogenesis and bone
absorption. As a result, growth factors are produced from the bone ECM,
promoting cancer cells growth. Regarding prostate cancer, and given that
osteoblasts express the androgen receptor (AR) and the expression of these
receptors increases as osteoblasts mature into osteocytes, there is a
possibility that androgens may also be implicated in the pathogenesis of bone
metastases [72,73]. Elevated BMP levels of prostate cancer cells or,
consequently, the presence of BMP in the bone microenvironment are important
factors for the colonization and survival of cancer cells in bone tissue. In an
earlier study, BMP-7 was detected in the majority of bone metastasis samples,
but not in normal bone samples [74]. BMP-2 could contribute to the formation of
osteolytic bone metastasis and induce osteoblast apoptosis, as suggested by a
similar study [75]. In addition, osteoblasts and osteocytes also release LIF
and activation of LIF receptors in breast cancer cells appears to keep them in
a state of inactivity. Loss of LIF receptors results in reduced expression of
genes involved in cell inactivity. Experimental knockdown of LIF receptors
increases the migration and penetration of cancer cells and the differentiation
of osteoclasts. Overexpression of PTHrP also reduces LIF receptors signalling
[76].
Scientific data have
shown that osteoblasts are important contributors in the pathogenesis of
metastatic bone disease, but their exact contribution to homing, dormancy, and
survival of the tumor cells has not yet been clarified. In comparison with osteoclasts,
the role of osteoblasts in bone metastasis and the formation of metastatic
niche is rather low and under-investigated. A better understanding of the
interaction of osteoblasts with cancer cells within the bone tissue will be
needed for the identification of novel management methods for patients with
bone metastatic disease.